研究者
J-GLOBAL ID:201901019174994968   更新日: 2024年01月30日

黒崎 創

Kurosaki Hajime
所属機関・部署:
職名: 助教
研究分野 (1件): 腫瘍生物学
競争的資金等の研究課題 (6件):
  • 2020 - 2023 卵巣癌に対する遠隔感染能を強化した腫瘍溶解性ワクシニアウイルスの開発
  • 2016 - 2020 新規人工染色体ベクターを用いた血友病に対する細胞補充療法の開発
  • 2014 - 2016 新規人工染色体ベクターを用いた血友病に対する再生補充療法の開発
  • 2012 - 2014 ゲノム補完人工染色体を用いた血友病遺伝子治療モデルの検討
  • 2009 - 2012 血友病治療のためのヒト人工染色体の開発
全件表示
論文 (15件):
  • Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, Nozomi Kuwano, Masato Yamane, Kenta Ishii, Yoshiyuki Fujiwara, Takafumi Nakamura. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Cells. 2021. 10. 5
  • Motomu Nakatake, Nozomi Kuwano, Emi Kaitsurumaru, Hajime Kurosaki, Takafumi Nakamura. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment. Molecular Therapy. 2020
  • Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, Midori Yamashita, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Science translational medicine. 2020. 12. 526
  • Motomu Nakatake, Hajime Kurosaki, Nozomi Kuwano, Kosuke Horita, Mai Ito, Hiromichi Kono, Tomotaka Okamura, Kosei Hasegawa, Yasuhiro Yasutomi, Takafumi Nakamura. Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function. Molecular therapy oncolytics. 2019. 14. 159-171
  • Horita K, Kurosaki H, Nakatake M, Ito M, Kono H, Nakamura T. Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochemical and biophysical research communications. 2019. 516. 3. 831-838
もっと見る
MISC (7件):
  • Motomu Nakatake, Hajime Kurosaki, Kosuke Horita, Nozomi Kuwano, Kenta Ishii, Miyuki Nomura, Teruhisa Sakamoto, Tomotaka Okamura, Yasuhiro Yasutomi, Takafumi Nakamura. Preclinical Study of Tumor-Targeted and Armed Oncolytic Vaccinia Virus for Systemic Cancer Virotherapy. MOLECULAR THERAPY. 2017. 25. 5. 59-59
  • N. Uno, K. Ueda, Y. Iida, Y. Yakura, H. Kurosaki, K. Uno, M. Osaki, T. Obayashi, Y. Kazuki, M. Hiratsuka, et al. Toward safe and effective gene- and cell-therapies using human artificial chromosomes and stem cells. CHROMOSOME RESEARCH. 2015. 23. 2. 368-368
  • Ikumi Goto, Naoyoshi Nitta, Motomu Nakatake, Nao Okada, Masato Yamane, Hajime Kurosaki, Takafumi Nakamura. Deletions of Both Vaccinia Growth Factor and O1 Protein Genes Enhance Therapeutic Index of Oncolytic Vaccinia Virus. MOLECULAR THERAPY. 2014. 22. S67-S68
  • 矢倉裕奈, 石原千恵, 藤井昂洸, 香月康宏, 黒崎創, 土井健史, 小松則夫, 押村光雄, 武谷浩之. ヒト人工染色体とiPS細胞を用いた新規血友病遺伝子治療法. 生化学. 2011. ROMBUNNO.2T15P-16
  • 黒崎創, 平塚正治, 香月康宏, 今岡奈津子, 石原知恵, 宇野愛海, 武谷浩之, 押村光雄. 血友病A型細胞補充療法を目指したヒト第VIII因子発現HACベクターの有用性の検討. 再生医療. 2010. 9
もっと見る
特許 (3件):
講演・口頭発表等 (2件):
  • Preclinical toxicological evaluation in cynomolgus monkey with tumor-targeted and armed oncolytic vaccinia virus purified through manufacturing process
    (第24回日本遺伝子細胞治療学会 2018)
  • Preclinical toxicological evaluation of tumor-targeted and armed oncolytic vaccinia virus in cynomolgus monkey
    (第23回日本遺伝子細胞治療学会 2017)
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る